Bioinformatics Analysis Identifies ASCL1 as the Key Transcription Factor in Hepatocellular Carcinoma Progression

Area of Science:

• Molecular Oncology
• Bioinformatics
• Cancer Genomics

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge with limited effective therapeutic strategies.
• Identifying novel molecular targets and understanding regulatory mechanisms are crucial for improving HCC prognosis.
• Dysregulation of transcription factors and their target genes plays a critical role in hepatocarcinogenesis.

Purpose of the Study:

• To identify key differentially expressed transcription factors (DETFs) and their target messenger RNAs (mRNAs) in HCC.
• To elucidate the functional role and prognostic significance of identified DETFs and target mRNAs in HCC progression.
• To investigate the potential of ASCL1 and SLC6A13 as therapeutic targets and prognostic biomarkers for HCC.

Main Methods:

• Bioinformatic analysis of gene expression data (GSE62232) to identify DETFs and differentially expressed genes (DEGs).
• Construction of regulatory networks and prognostic risk models to identify key DETFs.
• Binding site analysis, survival analysis, clinical characteristic analysis, and in vitro experiments to validate target genes and their functions in HCC cells.

Main Results:

• ASCL1 was identified as the key DETF, and SLC6A13 was predicted as its target mRNA, both downregulated in HCC.
• High SLC6A13 expression correlated with better HCC prognosis and differential expression in patients with varying clinical characteristics.
• Overexpression of ASCL1 and SLC6A13 suppressed HCC cell growth, invasion, and migration; ASCL1 overexpression upregulated SLC6A13 expression.

Conclusions:

• ASCL1 and SLC6A13 function as suppressor genes in HCC progression, with ASCL1 targeting SLC6A13.
• These genes hold promise as potential therapeutic targets and prognostic biomarkers for HCC.
• The findings provide new insights into the molecular mechanisms underlying HCC and suggest avenues for future research and treatment development.